Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| CG Oncology, Inc.CGON · Entity 3735 | Director | September 15, 2026 | September 17, 2026 |
| Fulgent Genetics, Inc.FLGT · Entity 2545 | Director | August 01, 2022 | August 03, 2022 |
| uniQure N.V.QURE · Entity 4162 | Director | June 10, 2026 | June 12, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
CG Oncology, Inc.
Report date September 15, 2026 · Filed September 17, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Ending reported balance
After 2026-09-15 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-09-15 · Exercise / conversion · Acquired 1,000 · Balance 1,000 Row 2 · 2026-09-15 · Sale · Disposed 1,000 · Balance 0 F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026. F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.54 to $73.52 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range. |
| Director Stock Option (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $0.60 · Expires 2028-07-08 | Direct | 103,077 |
Reported balance
After 2026-09-15 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-09-15 · Exercise / conversion · Disposed 1,000 · Balance 103,077 F3: Fully vested |
Filing footnotes · ownership attribution and instrument terms
F1: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 5, 2026.
F2: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $72.54 to $73.52 inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
F3: Fully vested
Fulgent Genetics, Inc.
Report date August 01, 2022 · Filed August 03, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 8,000 |
Reported balance
After 2022-08-01 transaction · row 1
1 source rowRow 1 · 2022-08-01 · Grant · Acquired 8,000 · Balance 8,000 F1: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after August 1, 2022, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after August 1, 2022, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date.
uniQure N.V.
Report date June 10, 2026 · Filed June 12, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Ordinary SharesSEC Table I · non-derivative | Direct | 35,494 |
Ending reported balance
After 2026-06-11 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-06-10 · Grant · Acquired 7,550 · Balance 37,487 F1: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Row 2 · 2026-06-11 · Sale · Disposed 1,993 · Balance 35,494 F2: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $26.82 · Expires 2036-06-10 | Direct | 13,980 |
Reported balance
After 2026-06-10 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-10 · Grant · Acquired 13,980 · Balance 13,980 F4: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.
F2: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person.
F3: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $26.92 to $27.25. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
F4: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| March 17, 2025 Filed Mar 18, 2025 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0000950170-25-041265 · ownership.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 130,077 Underlying: Common Stock · 1,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 1,000 | $28.00 | $28,000.00 |
DisclosureSEC source: 0000950170-25-041265 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024. Read SEC document |
| March 17, 2025 Filed Mar 18, 2025 20:30 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 1,000 | $0.60 | $600.00 |
DisclosureSEC source: 0000950170-25-041265 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0000950170-25-023182 · ownership.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 131,077 Underlying: Common Stock · 1,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 1,000 | $28.61 | $28,610.00 |
DisclosureSEC source: 0000950170-25-023182 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024. Read SEC document |
| February 18, 2025 Filed Feb 19, 2025 21:15 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 1,000 | $0.60 | $600.00 |
DisclosureSEC source: 0000950170-25-023182 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| January 13, 2025 Filed Jan 14, 2025 21:16 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionDirector Stock Option (right to buy) · Derivative | 1,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0000950170-25-005359 · ownership.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 132,077 Underlying: Common Stock · 1,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested Read SEC document |
| January 13, 2025 Filed Jan 14, 2025 21:16 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 1,000 | $29.66 | $29,660.00 |
DisclosureSEC source: 0000950170-25-005359 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024. Read SEC document |
| January 13, 2025 Filed Jan 14, 2025 21:16 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 1,000 | $0.60 | $600.00 |
DisclosureSEC source: 0000950170-25-005359 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 22:00 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionStock Option · Derivative | 1,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0000950170-24-137319 · ownership.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 133,077 Underlying: Common Stock · 1,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_date: Fully vested. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 22:00 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 1,000 | $28.84 | $28,840.00 |
DisclosureSEC source: 0000950170-24-137319 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024. Read SEC document |
| December 16, 2024 Filed Dec 17, 2024 22:00 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 1,000 | $0.60 | $600.00 |
DisclosureSEC source: 0000950170-24-137319 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 06, 2024 Filed Dec 6, 2024 23:51 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionStock Option · Derivative | 1,000 | $0.00 Strike: $0.60 | $0.00 |
DisclosureSEC source: 0000950170-24-134261 · ownership.xml · derivative · entry 4 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 134,077 Underlying: Common Stock · 1,000 shares Expires 2028-07-08 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_date: Fully vested. Read SEC document |
| December 06, 2024 Filed Dec 6, 2024 23:51 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 250 | $34.98 | $8,744.00 |
DisclosureSEC source: 0000950170-24-134261 · ownership.xml · nonDerivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024. F3 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $34.92 to $35.05. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| December 06, 2024 Filed Dec 6, 2024 23:51 UTC | CG Oncology, Inc. CGON · Entity 3735 | SaleCommon Stock | 750 | $34.40 | $25,797.98 |
DisclosureSEC source: 0000950170-24-134261 · ownership.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 250 F1 · kind: The sales reported were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on September 6, 2024. F2 · price: Represents the weighted average sale price for the entire number of shares sold. The actual sale prices range between $33.91 to $34.87. Detailed information on the exact number of shares sold at each sale price can be obtained from the Issuer upon request. Read SEC document |
| December 06, 2024 Filed Dec 6, 2024 23:51 UTC | CG Oncology, Inc. CGON · Entity 3735 | Exercise / conversionCommon Stock | 1,000 | $0.60 | $600.00 |
DisclosureSEC source: 0000950170-24-134261 · ownership.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 1,000 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 04, 2024 Filed Oct 7, 2024 21:17 UTC | CG Oncology, Inc. CGON · Entity 3735 | GrantStock Option (Right to Buy) · Derivative | 15,600 | $0.00 Strike: $36.63 | $0.00 |
DisclosureSEC source: 0000950170-24-113320 · ownership.xml · derivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,600 Underlying: Common Stock · 15,600 shares Expires 2034-10-03 F1 · derivative.exercise_date: 1/12th of the total number of shares of common stock subject to the option vest monthly following October 4, 2024, the date of grant, subject to the Reporting Person's continuous service to the Issuer through each vesting date. Read SEC document |
| June 19, 2024 Filed Jun 21, 2024 21:00 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 15,840 | $0.00 Strike: $4.57 | $0.00 |
DisclosureSEC source: 0000904454-24-000397 · edgar.xml · derivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,840 Underlying: Ordinary Shares · 15,840 shares Expires 2034-06-19 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 19, 2024 Filed Jun 21, 2024 21:00 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 8,080 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-24-000397 · edgar.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 24,079 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 13, 2024 Filed Jun 18, 2024 22:11 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,222 | $5.14 | $11,421.08 |
DisclosureSEC source: 0000904454-24-000385 · edgar.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,999 F1 · kind: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F1 · shares: The shares were sold upon the vesting of restricted share units solely to cover estimated withholding taxes, pursuant to automatic sale instructions included in the relevant Restricted Share Unit Agreement. The sale was not a discretionary trade by the Reporting Person. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $5.13 to $5.15. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 16, 2023 Filed Jun 20, 2023 21:28 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 2,291 | $18.83 | $43,139.53 |
DisclosureSEC source: 0000904454-23-000400 · edgar.xml · nonDerivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,221 F3 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F3 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F4 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $18.81 to $18.94. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| June 13, 2023 Filed Jun 20, 2023 21:28 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 17,060 | $0.00 Strike: $20.18 | $0.00 |
DisclosureSEC source: 0000904454-23-000400 · edgar.xml · derivative · entry 3 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,060 Underlying: Ordinary Shares · 17,060 shares Expires 2033-06-13 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 13, 2023 Filed Jun 20, 2023 21:28 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 8,700 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-23-000400 · edgar.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,512 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 27, 2023 Filed Mar 1, 2023 21:19 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 389 | $19.73 | $7,674.97 |
DisclosureSEC source: 0000899243-23-006594 · doc4.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,812 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. 386 of the shares were sold in multiple transactions at prices ranging from $19.66 to $19.97 and 3 of the shares were sold at $20.82. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| August 01, 2022 Filed Aug 3, 2022 21:44 UTC | Fulgent Genetics, Inc. FLGT · Entity 2545 | GrantCommon Stock | 8,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-22-044302 · doc4.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,000 F1 · shares: Restricted stock units. The shares subject to the restricted stock units vest over a period of four years, with 1/4th of such shares vesting 12 months after August 1, 2022, and 1/16th of such shares vesting at the end of every three month period thereafter over the remaining 36 months, subject to continued service for Issuer on each vesting date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:59 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 17,810 | $0.00 Strike: $14.08 | $0.00 |
DisclosureSEC source: 0000904454-22-000362 · edgar.xml · derivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,810 Underlying: Ordinary Shares · 17,810 shares Expires 2032-06-15 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| June 15, 2022 Filed Jun 17, 2022 20:59 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 9,080 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000362 · edgar.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,201 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 28, 2022 Filed Mar 2, 2022 22:45 UTC | uniQure N.V. QURE · Entity 4162 | SaleOrdinary Shares | 795 | $16.64 | $13,228.80 |
DisclosureSEC source: 0000904454-22-000221 · edgar.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,121 F1 · kind: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F1 · shares: As required by the relevant Restricted Share Unit Agreement, the Reporting Person sold the Ordinary Shares and remitted the proceeds therefrom to the Issuer to satisfy estimated tax withholding obligations triggered by the vesting of restricted share units. F2 · price: The price reported in Column 4 is a weighted average price. The shares were sold in multiple transactions at prices ranging from $16.64 to $16.80. The Reporting Person undertakes to provide to the Issuer, any shareholder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 23:43 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 2,645 | $0.00 Strike: $16.04 | $0.00 |
DisclosureSEC source: 0000904454-22-000199 · edgar.xml · derivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,645 Underlying: Ordinary Shares · 2,645 shares Expires 2032-02-24 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 24, 2022 Filed Feb 28, 2022 23:43 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 1,534 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-22-000199 · edgar.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,916 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:30 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock Option (Right to Buy) · Derivative | 4,107 | $0.00 Strike: $37.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000265 · edgar.xml · derivative · entry 2 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,107 Underlying: Ordinary Shares · 4,107 shares Expires 2031-02-25 F2 · derivative.exercise_date: The Stock Option vests 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| February 25, 2021 Filed Mar 1, 2021 21:30 UTC | uniQure N.V. QURE · Entity 4162 | GrantOrdinary Shares | 2,382 | $0.00 | $0.00 |
DisclosureSEC source: 0000904454-21-000265 · edgar.xml · nonDerivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,382 F1 · shares: Represents restricted share units granted to the Reporting Person under the Issuer's 2014 Share Incentive Plan, as amended and restated. Each restricted share unit represents the contingent right to receive one Ordinary Share. The restricted share units vest 100% on the first anniversary of the date of grant, subject to the Reporting Person's continued relationship with the Issuer through such date. Read SEC document |
| September 15, 2020 Filed Sep 17, 2020 16:28 UTC | uniQure N.V. QURE · Entity 4162 | GrantStock option (Right to Buy) · Derivative | 10,000 | $0.00 Strike: $38.67 | $0.00 |
DisclosureSEC source: 0000904454-20-000614 · edgar.xml · derivative · entry 1 POST LEONARD E · CIK 0001235862 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 10,000 Underlying: Ordinary Shares · 10,000 shares Expires 2030-09-15 F1 · derivative.exercise_date: The Stock Option vests over three years, with 33.33% vesting after twelve months from the date of grant and then 8.33% every three months thereafter, subject to the Reporting Person's continued relationship with the Issuer through each such date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.